Bristol-Myers, Pfizer Announce Positive Phase 3 Trial Results for ELIQUIS

Bristol-Myers
Squibb Company (NYSE: BMY) and Pfizer
Inc. (NYSE: PFE) today announced the results of the Phase 3
AMPLIFY-EXT trial, which evaluated treatment with ELIQUIS®
(apixaban) over a one-year period compared to placebo for the prevention
of recurrent venous thromboembolism (VTE) in 2,486 patients who had
already completed 6 to 12 months of anticoagulation treatment for VTE,
including deep vein thrombosis (DVT) or pulmonary embolism (PE). In the
trial, extended treatment with ELIQUIS 2.5 mg and 5 mg twice daily,
demonstrated superiority versus placebo in the reduction of the
composite endpoint of symptomatic, recurrent VTE and death from any
cause (11.6% in the placebo group, compared with 3.8% and 4.2% in the
ELIQUIS

See full press release